FRSW107
Phase 3Small molecule
FRSW107 is one of 4 small molecule programs targeting Severe Hemophilia a. It is currently in Phase 3.
1
Indications
5
Total Trials
3
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Severe Hemophilia a
#DrugCompanyPhaseTrials
1Hemlibra
RocheApproved
Valoctocogene Roxaparvovec
BioMarin PharmaceuticalPhase 3
FRSW107
KKaifeng Pharmaceutical (Group) Co., Ltd.
Phase 3
Marstacimab
PfizerPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Severe Hemophilia a3 trials
A Single-arm, Open-label, Multicenter Phase III Clinical Study Evaluating the Efficacy, Safety, and Immunogenicity of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-demand Treatment in Patients With Severe Hemophilia A (Adults and Adolescents) .
Active, not recruiting·HHangzhou Gensciences Biopharmaceutical Co., Ltd.·Phase 3·NCT07663903·60 enrolled
A Single-Arm, Open-Label, Multicenter Phase III Clinical Study Evaluating the Efficacy, Safety, Immunogenicity and Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Therapy in Patients With Severe Hemophilia A (Adults and Adolescents)
Active, not recruiting·HHangzhou Gensciences Biopharmaceutical Co., Ltd.·Phase 3·NCT07684898·60 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for FRSW107. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details